The Conflict of Interest Bill introduced in the Rajya Sabha is a welcome step to control the grey areas in which “public private partnerships” are conducted. AMONG the many things that have proliferated in the economic boom of the brash new India is conflict of interest. So widespread, comprehensive and many-tentacled has this feature become that it is often no longer even recognised to exist, much less to be a...
More »SEARCH RESULT
Total Matching Records found : 501
How PH Kurien took on global patents system to make very costly drug affordable for poor-Arvind Panagariya
It is said that only God and a few good men and women run India. One such man is P H Kurien. For readers unfamiliar with his name, Kurien was India's Controller General of Patents, Designs & Trade Marks until March 12, 2012. On March 9, 2012, just three days before he left office, he issued the first-ever compulsory licence in India for the manufacture of a drug still under patent....
More »With slowing growth, people are now questioning the long-term Indian story
-The New York Times India's coalition government just celebrated the third anniversary of its tenure with a self-congratulatory banquet that could not have been more poorly timed: India's currency, the rupee, is falling; investment is down; inflation is rising; and deficits are eating away at government coffers. While short-term growth has slowed but not ground to a halt, India's problems have dampened hopes that it, along with China and other non-Western economies,...
More »Pills and shills
-The Indian Express Drug regulation is a mess. Everyone who propped up this irresponsible system is to blame Last week, a parliamentary standing committee on health delivered a thoroughly damaging report on the state of drug regulation in India, and the collusion between the regulator, industry and the medical profession that puts patients last. Over 118 pages, it said that the Drug Controller General of India (DCGI) and the Drug Standards Control...
More »Bayer demands withdrawal of Natco Pharma's compulsory licence-Khomba Singh
German drugmaker Bayer AG has demanded the withdrawal of the country's first compulsory licence given to Natco Pharma, arguing that a three-fourth reduction in the price of the anti-cancer drug by another Indian firm has made the permit redundant and its patent itself is vulnerable to being revoked. In March, India allowed Natco Pharma to legally make and sell a low-cost version of cancer drug Nexavar at 3% of the original...
More »
